(Corrects paragraph 1 to say the drug was compared to another drug and not a placebo)
July 18 (Reuters) - Celgene Corp said it will stop a late-stage trial of its blood cancer drug Revlimid after it observed a higher number of deaths in patients taking the drug compared to those on another treatment.
The trial was placed on a clinical hold by the U.S. Food and Drug Administration on July 12, Celgene said. The study was testing the drug in previously untreated, elderly patients with B-cell chronic lymphocytic leukemia.
Reporting by Esha Dey in Bangalore; Editing by Sreejiraj Eluvangal